Friday, 22 Mar 2019

You are here

Time to Rethink Gout as a Chronic Disease

The current issue of JAMA has a perspective article on Gout’s bad rap as dietary disease rather than the complex, chronic inflammatory disorder that is ineffectively treated in many. 

The author and experts interviewed believe that the pipeline of new drugs for gout will fuel the future of evidence-based care and more informed lifestyle instruction.

Gout affects about 4% of adults in the United States. The growing number of older adults, who are more likely to have gout, is expected to increase the need for gout care.

"The disease of kings" is clearly a misnomer as gluttony and excess seldom stand in the way of better care.  Sadly, many with gout fail to recognize it as a form of arthritis,  A 2016 online survey showed that 71% didn’t know gout and that half with gout were embarrassed by their condition. 

Although diet is often implicated, evidence proving the benefits of strict avoidance are limited.  While red meat, alcohol, sugar-sweetened soft drinks, and seafood have been implicated, the ACR guideline suggests that avoidance of purine-rich organ meats (liver), shellfish and sardines may only improve serum uric acid levels by10% to 18%.

Many experts have noted the limitations and pitfalls with found with a dietary approach to gout. 

A real problem are the differing treatment approaches and understanding of gout by primary care physicians (PCPs) and rheumatologist, exemplified by their contrasting guidelines. The 2012 ACR focuses on a a treat-to-target approach with the goal of a uric acid levels below 6 mg/dL and the use of urate-lowering medications long-term with frequent monitoring.  Yet the 2016 American College of Physicians guideline only has a treat-to-symptoms approach emphasizing the use of anti-inflammatory medications to control flares and reserving uric acid-lowering therapy for patients with frequent flares, 

Discrepancies between the guidelines may be hampering patient care, and hopefully upcoming meetngs between the ACR and ACP may resolve these differences. The ACR’s gout guideline is scheduled for release in 2020.

Emerging evidence suggests that a chronic disease care model for gout, which simultaneously addresses uric acid levels, lifestyle, and dietary factors, may improve management and outcomes for patients with gout.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Ironwood Retreats from the US Gout Market

Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019. In addition the Duzallo and Zurampic Patient Savings Program were also discontinued on December 31, 2018.

The company stated that this was a financial decision unrelated to the efficacy or safety of lesinurad.

Allopurinol Reduces Cardiovascular Outcomes in Diabetes

A Canadian study has shown that elderly diabetics who take allopurinol have a significant reduction in cardiovascular outcomes.  

Hyperuricemia has been shown to be a biomarker for cardiovascular outcomes in multiple disorders. These investigators studied the effect of allopurinol and mortality on CV outcomes in a population-based retrospective cohort study from Ontario, Canada.

FDA Slaps a Boxed Warning on Febuxostat for CV Risk

The U.S. Food and Drug Administration (FDA) has reviewed data from the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial and concluded there is an increased risk of death with Uloric (febuxostat) compared with allopurinol, and has added this as a boxed warning to the drug’s product label.

U.S. Gout Rates Remain Steady, but Substantial

Using data from 5,467 adults in the US in the National Health and Nutrition Examination Survey (NHANES) for the years 2007-2016, researchers found that the prevalence of gout and hyperuricemia has remained at 3.9%, having doubled from the 1960s to the 1990s, corresponding to an estimated 9.2 million adults with gout in 2015-2016.

Febuxostat Gets Reprieve from FDA Advisory Panel

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) study. 

The Vote